Core D, the Neuropathology Core (NP Core), is a continuation of the same core that has served the ADRC for the past 4 years. The personnel are the same except for a recently hired histology technician. Because Dr. Bruce Miller and the Clinical Core have recruited patients with FTDs and atypical dementing disorders throughout Northern California and beyond, we have hired Glen Oaks Pathology Services (San Francisco) to remove brains from enrolled patients within a 150 mile radius from UCSF. The chilled brain is transported to Dr. Eric Huang at the San Francisco VA Medical Center where the first of three brain dissection steps is performed: Dr. Huang coronally sections the fresh brain and alternate slabs are either immersion fixed in paraformaldehyde or frozen. Next, the fixed brain slabs are transported to Dr. William Seeley's laboratory at the UCSF Mission Center Building (MCB). Dr. Seeley has been studying selective neuronal vulnerability in FTD in close collaboration with Dr. DeArmond and the NP Core. Dr. Seeley dissects brain regions of interest for his studies and also performs dissections for other ADRC investigators. Finally, the remaining fixed brain samples are sent to Dr. DeArmond's Lab (adjacent to Dr. Seeley's) for removal of ~30 blocks of tissue for diagnostic neuropathological analysis. Dr. DeArmond and his staff perform multiple neurohistological and immunohistochemical stains on the blocks, perform semiquantitiatve analysis of the stained slides, write a detailed neuropathology final report on each case, and complete a NACC form. The NP Core provides quality digital photographs and quantitative morphometric analysis of neuropathological changes as needed for publications. The overall aim of this ADRC is to better understand the clinical heterogeneity of patients with AD, FTD and related disorders, and to tackle the problem of selective vulnerability. Complimentary to the clinical aim, the overall aim of the NP Core is to better understand the overlap of multiple different clinically and neuropathologically defined entities we are finding in many dementia patients. Through a consortium arrangement with Dr. Daniel Geschwind at UCLA, the NP Core will oversee transport of blood samples to his lab for differential genetic analysis of heterogeneity.
This core will provide a unique resource to dementia neuroscience investigators at the UCSF ADRC and beyond by systematically banking brain tissue and genetic materials from patients with AD, FTD, and other dementias. These resources are intended to facilitate modern neuroscientific research studies related to these disorders that will ultimately lead to new treatments.
|Orr, Anna G; Lo, Iris; Schumacher, Heike et al. (2018) Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis 110:29-36|
|Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064|
|Watson, Christa L; Possin, Katherine; Allen, I Elaine et al. (2018) Visuospatial Functioning in the Primary Progressive Aphasias. J Int Neuropsychol Soc 24:259-268|
|Casaletto, K B; Elahi, F M; Fitch, R et al. (2018) A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? Cytokine 111:481-489|
|Tan, Chin Hong; Fan, Chun Chieh; Mormino, Elizabeth C et al. (2018) Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathol 135:85-93|
|Mok, Sue-Ann; Condello, Carlo; Freilich, Rebecca et al. (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25:384-393|
|Sturm, Virginia E; Brown, Jesse A; Hua, Alice Y et al. (2018) Network Architecture Underlying Basal Autonomic Outflow: Evidence from Frontotemporal Dementia. J Neurosci 38:8943-8955|
|Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306|
|Bonham, Luke W; Geier, Ethan G; Steele, Natasha Z R et al. (2018) Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. Front Neurosci 12:476|
|Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858|
Showing the most recent 10 out of 590 publications